Growth-factor Enhanced Matrix(ZymoGenetics, Inc.)(Growth-factor Enhanced Matrix(ZymoGenetics, Inc.)) - 药物靶点：PDGFRs_在研适应症：骨病_专利_临床

概要

基本信息

药物类型

生长因子

别名

B-TCP Plus、GEMESIS

+ [2]

靶点

PDGFRs

作用方式

激动剂、刺激剂

作用机制

PDGFR激动剂(血小板衍生生长因子受体激动剂)、骨生成刺激剂

治疗领域

皮肤和肌肉骨骼疾病

在研适应症

骨病

非在研适应症-

原研机构

ZymoGenetics, Inc.

在研机构

ZymoGenetics, Inc.

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

加拿大 (2007-01-01),

骨病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 Growth-factor Enhanced Matrix(ZymoGenetics, Inc.) 相关的临床试验

CTRI/2024/10/075648

/ Not yet recruiting临床3期IIT

Recombinant human platelet-derived growth factor or urea cream in prevention of multitargeted kinase inhibitor-associated hand foot skin reaction: a randomized controlled trial - NIL

开始日期2024-11-27

申办/合作机构-

NCT06162832

/ Recruiting临床2期IIT

Evaluation of Clinical and Radiographic Parameters in Bony Defects Treated With Recombinant Human Platelet-derived Growth Factor in Combination With Allograft

Growth factors are defined as small proteins that trigger a cellular response after binding to cell receptors; Tissue engineering is now clinically applicable in a commercially available system involving the use of recombinant human platelet-derived growth factor.
The objective of this study is to evaluate clinical and radiographic parameters in bone defects treated with platelet-derived growth factor in combination with allograft.
Our hypothesis: Defects treated with DFDBA and rhPDGF-BB have better clinically and radiographic results that the defects treated with DFDBA and saline solution.

开始日期2024-01-10

申办/合作机构

Universidad Autónoma de Nuevo León

[+2]

NCT04786327

/ Completed临床2期IIT

Intrabony Defects Management Using Growth Factor Enhanced Matrix Versus Platelet Rich Fibrin Utilizing Minimally Invasive Surgical Technique. A Randomized Clinical and Radiographic Trial.

Twenty-one intra-bony defects in fifteen systemically healthy patients with moderate to severe chronic periodontitis were randomly classified into 3 groups, 7 sites each. Group І treated by MIST alone, group ІІ treated by MIST + ethylenediamine-tetraaceticacid (EDTA) + PRF and group III treated by MIST + EDTA + GEM 21S. The clinical parameters including probing pocket depth (PPD), clinical attachment level (CAL) and bleeding on probing (BOP), were recorded at baseline, 3, 6 and 9 months post-surgery. Cone beam computed tomography (CBCT) was performed at baseline and 9 months post-surgery to evaluate bone level and bone density

开始日期2018-01-01

申办/合作机构

Tanta University

100 项与 Growth-factor Enhanced Matrix(ZymoGenetics, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Growth-factor Enhanced Matrix(ZymoGenetics, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Growth-factor Enhanced Matrix(ZymoGenetics, Inc.) 相关的专利（医药）

登录后查看更多信息

45

项与 Growth-factor Enhanced Matrix(ZymoGenetics, Inc.) 相关的文献（医药）

2024-07-01·Journal of Indian Society of Periodontology

Effectiveness of vestibular incision subperiosteal tunnel access technique in the treatment of multiple adjacent gingival recession defects: A systematic review

Article

作者: Lathiya, Vrushali Nilesh ; Kolte, Abhay Pandurang ; Tuli, Prabhnoor ; Kolte, Rajashri Abhay

Objective:To investigate the effectiveness of Vestibular Incision Subperiosteal Tunnel Access (VISTA) technique over other root coverage (RC) procedures for treating Millers Class I and II multiple adjacent gingival recession defects (MAGRD).Methods:Patient, Intervention, Comparison, and Outcome question was established, and a literature review was carried out across PubMed, Cochrane Libraries, EMBASE, and hand-searched journals till April 2023 to identify the clinical research on the effectiveness of the VISTA Technique for RC procedures. Only randomized controlled trials (RCTs) with a minimum of 6 months’ follow-up were considered. The outcomes assessed were complete RC (CRC), width of keratinized gingiva, and gingival thickness.Results:A total of 30 articles were retrieved and ultimately 7 RCTs that met the inclusion criteria were incorporated into the systematic review. VISTA with biomaterials showed significant improvements in all the treatment outcomes over other RC procedures. Specifically, VISTA + subepithelial connective tissue graft (CTG)/CTG achieved an average CRC of 93.95%, along with significant increase in other parameters. In addition, biomaterials such as platelet concentrates, collagen membrane, Bioguide enhanced GEM21S, and Acellular dermal matrix proved viable alternatives producing similar outcomes.Conclusion:VISTA technique is an effective procedure for treating MAGRD in terms of achieving CRC over other RC procedures. In addition, the use of biomaterials further enhances the treatment outcomes.

2024-03-01·The International Journal of Periodontics & Restorative Dentistry

Effect of Recombinant Human Platelet-Derived Growth Factor on Healing of Chronic Periapical Tissue Pathosis Following Apical Surgery in a Canine Model: A Histomorphometric and Microcomputed Tomography Analysis

Article

作者: Al Hezaimi, Khalid ; Naghshbandi, Jafar ; Rotstein, Ilan

This canine in vivo study assessed the effect of recombinant human platelet-derived growth factor (rhPDGF) on the healing of periapical tissues following apical surgery. From a total of 96 premolar teeth, 64 teeth from six beagle dogs (2 years old) were classified as experimental and were randomly assigned to four experimental groups (16 teeth per group). After having the pulp extirpated, leaving teeth open to the oral cavity for 1 week, and sealing with an immediate restorative material for 8 weeks, nonsurgical endodontic treatment was performed. A split-mouth design was used, and intra-animal randomization of treatment sides was applied to the groups as follows: apical curettage + 1.5-mm root-end resection (Group 1); apicoectomy + mineral trioxide aggregate (MTA) root-end filling (Group 2); apicoectomy + MTA root-end filling + rhPDGF (Group 3); and apical curettage + rhPDGF (Group 4). The animals were sacrificed 24 months after apical surgery, and histologic and μCT analyses were performed for bone volume loss (BVL). Group 1 showed partial resolution of the periapical lesions without signs of tissue regeneration (BVL: 49.09 ± 10.97 mm3). Group 2 had minimal bone regeneration and showed cementum reformation in 9 teeth, with no direct attachment to the MTA (BVL: 35.34 ± 10.97 mm3). Group 3 showed regeneration of all damaged apical tissues without direct contact between the cementum and MTA (BLV: 4.51 ± 1.55 mm3). Group 4 showed regeneration of PDL, bone, and cementum and attachment of functional cementum fibers (BVL: 2.82 ± 2.3 mm3). The difference in BVL was statistically significant only for Groups 1 and 2 (P < .05). rhPDGF may help regenerate apical tissue structures following apical surgery.

2023-10-01·Journal of Orthopaedics

A retrospective review of recombinant human platelet-derived growth factor with beta-tricalcium phosphate bone graft substitute use in hindfoot and/or ankle arthrodesis

Article

作者: Loveland, Jeffrey D

BackgroundNonunion following foot and ankle arthrodesis can cause chronic pain and disability, poor patient satisfaction, and increased healthcare costs. Nonunion rates are reported in 10%-12% of primary foot and/or ankle arthrodesis procedures, with significantly greater rates among patients with high-risk factors such as smoking, diabetes, obesity, or Charcot neuroarthropathy. Recombinant human platelet-derived growth factor BB-homodimer with beta-tricalcium phosphate (rhPDGF-BB/β-TCP) is a bone graft substitute that has demonstrated efficacy in foot and ankle fusion rates that are comparable to autograft.MethodsCharts and radiographs were retrospectively reviewed on consecutive adult patients undergoing talonavicular, calcaneal-cuboid, subtalar, and/or ankle arthrodesis utilizing rhPDGF-BB/β-TCP bone graft substitute. The primary outcome measures were rate of and mean time to fusion, mean time to return to function, and incidence of adverse events.ResultsThis study reviewed133 patients who underwent 209 hindfoot and/or ankle joint arthrodesis procedures with a mean follow-up 20.34 ± 11.05 months. The overall fusion rate was 92.82% (194/209 joints) with a mean time to fusion of 13.14 ± 2.52 weeks and return to function of 16.56 ± 3.26 weeks. Overall, there were 7 (5.26%) patients who experienced an adverse event (AE) with 15 (7.18%) joints experiencing a nonunion.ConclusionFusion rates with rhPDGF-BB/β-TCP bone grafting material compared favorably to autograft controls when used in hindfoot and/or ankle arthrodesis. No AEwas related to rhPDGF-BB/β-TCP. This study suggests that using rhPDGF-BB/β-TCP is effective in hindfoot and/or ankle arthrodesis, even among patients with comorbidities who are at a higher risk of developing a nonunion.Level of clinical evidence3.

100 项与 Growth-factor Enhanced Matrix(ZymoGenetics, Inc.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	M05	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
骨病	加拿大	ZymoGenetics, Inc.	2007-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed \| Int J Periodontics Restorative Dent	N/A	牙龈退缩	15	GEM 21S	鏇簾獵簾餘醖鑰鏇鏇網(願膚獵觸醖構鏇願願獵) = higher in the VISTA group compared with the PPG group 夢壓艱艱淵醖餘網膚遞 (鹹範鹽齋壓鑰窪壓簾觸 ) 更多	-	2016-03-01